Meghalaya Magazine

Persistent Epithelial Defect Market, Epidemiology & Market Forecast – 2030

 Breaking News
  • No posts were found

Persistent Epithelial Defect Market, Epidemiology & Market Forecast – 2030

September 07
17:42 2021
Persistent Epithelial Defect Market, Epidemiology & Market Forecast - 2030
DelveInsight Business Research LLP
DelveInsight’s ‘Persistent Epithelial Defect Market’ report deliver an in-depth understanding of the Persistent Epithelial Defect, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Persistent Epithelial Defect Market

The Persistent Epithelial Defect market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted PED symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Persistent Epithelial Defect symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Persistent Epithelial Defect Market Outlook

The Persistent Epithelial Defect market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Persistent Epithelial Defect market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

This segment gives a thorough detail of Persistent Epithelial Defect market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Persistent Epithelial Defect market in 7MM is expected to change in the study period 2018–2030.

Key Findings

This section includes a glimpse of the Persistent Epithelial Defect market in 7MM. The market size of PED in the seven major markets was found to be USD 165.3 million in 2020, and the market is estimated to increase for the study period (2018–2030).

The United States Market Outlook

This section provides a total of Persistent Epithelial Defect market size and market size by therapies in the United States.

The United States accounts for the highest PED market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

EU-5 Countries: Market Outlook

The total Persistent Epithelial Defect market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Persistent Epithelial Defect market size and market size by therapies in Japan are also mentioned.

Request for sample pages @ Persistent Epithelial Defect Market Size 

Table of contents 

1. Key Insights

2. Report Introduction

3. Persistent Corneal Epithelial Defects Market Overview at a Glance

3.1. Market Share (%) Distribution of Persistent Corneal Epithelial Defects in 2018

3.2. Market Share (%) Distribution of Persistent Corneal Epithelial Defects in 2030

4. Executive Summary of Persistent Corneal Epithelial Defects

5. Organizations contributing towards Persistent Epithelial Defect

6. Disease Backgroung and Overview

6.1. Introduction

6.2. Etiology

6.3. Clinical Presentation

6.4. Pathophysiology

6.5. Diagnosis

6.5.1. Differential diagnosis

7. Unmet Needs

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. 7MM Total Incident Patient Population of Persistent Corneal Epithelial Defects

8.3. Assumption and Rationale

8.4. The United States

8.4.1. Incident Cases of Persistent Corneal Epithelial Defects in the United States

8.4.2. Incident cases of PED based on Gender in the United States

8.4.3. Etiology-specific Incidence of Persistent Corneal Epithelial Defects in the United States

8.5. EU5

8.6. Germany

8.6.1. Incident Cases of Persistent Corneal Epithelial Defects in Germany

8.6.2. Incident cases of PED based on Gender in Germany

8.6.3. Etiology-specific Incidence of Persistent Corneal Epithelial Defects in Germany

8.7. France

8.7.1. Incident Cases of Persistent Corneal Epithelial Defects in France

8.7.2. Incident cases of PED based on gender in France

8.7.3. Etiology-specific Incidence of Persistent Corneal Epithelial Defects in France

8.8. Italy

8.8.1. Incident Cases of Persistent Corneal Epithelial Defects in Italy

8.8.2. Incident cases of PED based on Gender in Italy

8.8.3. Etiology-specific Incidence of Persistent Corneal Epithelial Defects in Italy

8.9. Spain

8.9.1. Incident Cases of Persistent Corneal Epithelial Defects in Spain

8.9.2. Incident cases of PED based on Gender in Spain

8.9.3. Etiology-specific Incidence of Persistent Corneal Epithelial Defects in Spain

8.10. United Kingdom

8.10.1. Incident Cases of Persistent Corneal Epithelial Defects in the United Kingdom

8.10.2. Incident cases of PED based on Gender in the United Kingdom

8.10.3. Etiology-specific Incidence of Persistent Corneal Epithelial Defects in the United Kingdom

8.11.Japan

8.11.1. Incident Cases of Persistent Corneal Epithelial Defects in Japan

8.11.2. Incident cases of PED based on Gender in Japan

8.11.3. Etiology-specific Incidence of Persistent Corneal Epithelial Defects in Japan

9. Current Treatment Practices

10. Patient Journey

11. Case Report

12. Marketed Therapies

12.1. OXERVATE: Dompe Farmaceutici

12.1.1. Product Description

12.1.2. Regulatory Milestones

12.1.3. Other Developmental Activities

12.1.4. Clinical Development

12.1.5. Safety and Efficacy

12.1.6. Product Profile

13. Emerging Products

13.1. Nexagon: OcuNexus Therapeutics/Eyevance Pharmaceuticals

13.1.1. Drug Descriptions

13.1.2. Other Developmental Activities

13.1.3. Clinical Development

13.1.4. Clinical Trials Information

13.1.5. Safety and Efficacy

13.1.6. Product Profile

13.2. ST266: Noveome Biotherapeutics

13.2.1. Drug Description

13.2.2. Other Developmental Activities

13.2.3. Clinical Development

13.2.4. Clinical Trials Information

13.2.5. Safety and Efficacy

13.2.6. Product Profile

13.3. RGN-259: RegeneRx Biopharmaceuticals

13.3.1. Drug Description

13.3.2. Other Developmental Activities

13.3.3. Clinical Development

13.3.4. Clinical Trials Information

13.3.5. Safety and Efficacy

13.3.6. Product Profile

13.4. REC-0559: Recordati Rare Diseases/Mimetech

13.4.1. Drug Descriptions

13.4.2. Other Developmental Activities

13.4.3. Clinical Development

13.4.4. Clinical Trials Information

13.4.5. Safety and Efficacy

13.4.6. Product Profile

14. Persistent Corneal Epithelial Defects: 7 Major Market Analysis

14.1. Key Findings

14.2. Market Size of Persistent Corneal Epithelial Defects in 7MM

14.3. Market Size of Persistent Corneal Epithelial Defects by Therapies

15. Market Outlook

15.1. United States Market Size

15.1.1. Total Market Size of Persistent Corneal Epithelial Defects in United States

15.1.2. Market Size of Persistent Corneal Epithelial Defects by Therapies in United States

15.2. EU-5 Market Size

15.3. Germany

15.3.1. Total Market size of Persistent Corneal Epithelial Defects in Germany

15.3.2. Market Size of Persistent Corneal Epithelial Defects by Therapies in Germany

15.4. France

15.4.1. Total Market size of Persistent Corneal Epithelial Defects in France

15.4.2. Market Size of Persistent Corneal Epithelial Defects by Therapies in France

15.5. Italy

15.5.1. Total Market size of Persistent Corneal Epithelial Defects in Italy

15.5.2. Market Size of Persistent Corneal Epithelial Defects by Therapies in Italy

15.6. Spain

15.6.1. Total Market size of Persistent Corneal Epithelial Defects in Spain

15.6.2. Market Size of Persistent Corneal Epithelial Defects by Therapies in Spain

15.7. United Kingdom

15.7.1. Total Market size of Persistent Corneal Epithelial Defects in United Kindgom

15.7.2. Market Size of Persistent Corneal Epithelial Defects by Therapies in United Kingdom

15.8. Japan

15.8.1. Total Market size of Persistent Corneal Epithelial Defects in Japan

15.8.2. Market Size of Persistent Corneal Epithelial Defects by Therapies in Japan

16. Market Drivers

17. Market Barriers

18. KOL Views

19. SWOT Analysis

20. Appendix

20.1. Bibliography

21. Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/